Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198668 | 0.83 | UGT2B7 (0.36) | HTR2AHTR2CHTR2BUGT2B7 | |
| SCHEMBL6887508 | 0.80 | UGT2B7 (0.31) | UGT2B7 | |
| SCHEMBL295332 | 0.80 | UGT2B7 (0.31) | UGT2B7 | |
| SCHEMBL6896467 | 0.78 | — | — | |
| SCHEMBL3249688 | 0.77 | TYR (0.33) | UGT2B7 | |
| SCHEMBL2502578 | 0.77 | TSHR (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL2498027 | 0.77 | CYP1A2 (0.31) | — | |
| SCHEMBL6896470 | 0.76 | LARS1 (0.31) | — | |
| SCHEMBL20562141 | 0.75 | — | — | |
| SCHEMBL7306721 | 0.75 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060292657-A1 | Phex substrates and methods using same | ENOBIA PHARMA INC. (CA) | 2006-12-28 | — | — | US | disclosed |
| WO-2004085465-A1 | PHEX SUBSTRATES AND METHODS USING SAME | ENOBIA PHARMA INC. (CA) | 2004-10-07 | — | — | WO | disclosed |
| US-20010046668-A1 | Fluorescence polarization method for determining protease activity | G.D. SEARLE & CO. (US) | 2001-11-29 | — | — | US | disclosed |
| US-5708137-A | Reagent and method for determining activity of herpes protease | G.D. SEARLE & CO. (US) | 1998-01-13 | — | — | US | disclosed |
| US-5506115-A | FLUOROGENIC PEPTIDES AS SUBSTRATES FOR ASSAY | G. D. SEARLE & CO. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0435845-B1 | Reagent and method for determining activity of retroviral protease | UNIV WASHINGTON (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5164300-A | Fluorescence, AIDS | WASHINGTON UNIVERSITY (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0435845-A1 | Reagent and method for determining activity of retroviral protease | WASHINGTON UNIVERSITY (US) | 1991-07-03 | — | — | EP | disclosed |
| US-5011910-A | Heptapeptides having fluorogenic and quenching groups as substrates for protease; colorimetric analysis, efficiency | WASHINGTON UNIVERSITY (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046668-A1 | Fluorescence polarization method for determining protease activity | PRSS1, PRSS3, MMP3 | HTR2A 3907/4885HTR2C 4389/4885HTR2B 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.